Van beleggers
voor beleggers
desktop iconMarkt Monitor

Inloggen

  • Geen account? Registreren

Wachtwoord vergeten?

Immutep(LAG-3 specialist), belangrijke speler in een nieuw checkpoint voor blockbuster drugs

218 Posts
Pagina: «« 1 2 3 4 5 6 ... 11 »» | Laatste | Omlaag ↓
  1. forum rang 4 Dag Trader 3 juni 2021 09:21
    hier even nog goed stuk van 18 mei....

    LAG3 - The Next Blockbuster Checkpoint? The Answer Increasingly Looks like a Yes. Not Just Due to Inhibition of LAG3, but its Activation as Well...and Perhaps More So the Latter.
    That Makes Immutep, an Underfollowed & Overlooked Pure-Play on LAG3, a Bargain at Current Levels.

    seekingalpha.com/article/4429440-immu...
  2. forum rang 4 Dag Trader 3 juni 2021 18:11
    uit de operational update van 7 mei:

    INSIGHT-004 - Phase I clinical trial
    The INSIGHT-004 study is expected to deliver final data at ASCO 2021 in a poster discussion.

    weet niet of dit al "final" was in het abstract 2518, is voor mij als niet-wetenschapper geen pijl aan vast te knopen ;-)

    hoop dat hier een verse link komt te staan vanavond:
    conferences.asco.org/am/dates-know
  3. forum rang 7 holenbeer 3 juni 2021 23:55
    Deze 2 wisten we al, toch?

    Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma.

    Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.

    meetinglibrary.asco.org/record/197989...
  4. forum rang 4 Dag Trader 4 juni 2021 08:55


    positive data!

    www.immutep.com/files/content/investo...,%20Efti,%20at%20ASCO%202021%20-%2004Jun2021.pdf

    (werkt deze link wel? :=p)
    cdn-api.markitdigital.com/apiman-gate...

    Immutep Reports Positive Data from its
    TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021
    • Combination therapy with eftilagimod alpha and pembrolizumab demonstrates very favourable
    overall response rate (ORR) together with favourable duration and depth of responses in 1
    st line
    NSCLC (41.7%, 2 CRs; minimum DoR > 6 months) and 2nd line HNSCC (29.7% ORR, 5 CRs; minimum
    DoR > 6 months)
    • Tumor responses seen in all PD-L1 subgroups, including low PD-L1 expressing patients (i.e. patients
    with TPS < 50%) which are typically less responsive to anti-PD-1 therapy
    • Secondary endpoints including progression free survival (PFS) and overall survival (OS) are trending
    very favourably in both indications (e.g. median PFS in 1st line NSCLC is 8.2 months and median OS in
    2nd line HNSCC is 12.6 months)
    • Combination therapy is safe and well tolerated
  5. forum rang 4 Dag Trader 4 juni 2021 09:15
    en TACTI-004

    cdn-api.markitdigital.com/apiman-gate...

    zie ook de website van Immutep

    Immutep Reports Positive Final Data from the
    INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021
    • Encouraging activity signals from the combination of efti and avelumab with a response rate of 41.7%
    in different solid tumours (DCR 50%) acc. to RECIST 1.1
    • No selection of patients for immunogenic markers (e.g. PD-L1 expression levels, MSI high or TMB)
    • 9 out of 12 patients still alive
    • Deep and durable responses also in patients with low or no PD-L1 expression and typically IO
    insensitive indications like gastroesophageal or cervical cancer which typically do not respond to
    immune checkpoint therapy
    • Continued good safety profile and promising activity signals warrant further clinical evaluation

  6. forum rang 4 Dag Trader 4 juni 2021 09:59
    quote:

    M-online schreef op 4 juni 2021 09:26:


    De terminologie die ze gebruiken geeft echt heel veel enthousiasme aan. Tumor responses in all subgroups. Echt een goed bericht. Voor de patiënten en voor immutep.


    zeker! ik hoop dat snel mensen die er echt verstand van hebben het in het nieuws gaan plaatsen! :-)

    nog een paar minuten... kijken of er dan voorbeurs al actie is....
218 Posts
Pagina: «« 1 2 3 4 5 6 ... 11 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Indices

AEX 792,40 0,00%
EUR/USD 1,1713 +0,17%
Germany30^ 15.632,60 +0,81%
Gold spot 1.763,61 -0,26%
LONDEN-FTSE 100 7.083,37 0,00%
NY-Nasdaq Composite 14.896,85 +1,02%

Stijgers

AALBER...
0,00%
ABN AM...
0,00%
Accell
0,00%
Accsys
0,00%
Acomo
0,00%

Dalers

AALBER...
0,00%
ABN AM...
0,00%
Accell
0,00%
Accsys
0,00%
Acomo
0,00%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links